Table 2.
Studies selected after searching at https://clinicaltrials.gov/ (accessed on 1 April 2023).
| No. | NCT No. | Study Title | Interventions/Study Design | Number Enrolled | Outcome Measures/OBS. |
|---|---|---|---|---|---|
| 1 | NCT01407172 | Hydrogen Sulfide and Peripheral Arterial Disease [122] | Observational | 252 | Plasma free H2S, nmol/L: No Vasc Disease, n = 53: 368.53 ± 20.8; Vasc Disease, n = 140: 441.04 ± 15.40 (p = 0.010); PAD, n = 13: 514.48 ± 62.05 (p = 0.007) |
| 3 | NCT02546323 | A Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima–Media Thickness in Chinese Subjects With Subclinical Atherosclerosis | Drug: Rosuvastatin Drug: Placebo |
543 | Percent in Lipid, Lipoprotein, and Apolipoprotein |
| 4 | NCT01327846 | Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) | Drug: Canakinumab Drug: Placebo |
10,066 | Adverse Events |
| 5 | NCT01663402 | ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes after an Acute Coronary Syndrome during Treatment with Alirocumab | Drug: Alirocumab Drug: Placebo |
18,924 | Adverse Events |
| 6 | NCT03001076 | Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients with Elevated LDL-C (CLEAR Tranquility) |
Drug: Bempedoic acid Drug: Ezetimibe Other: Placebo |
269 | Percent in Lipid, Lipoprotein, and Apolipoprotein Adverse Events |
| 7 | NCT03067441 | Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE) |
Drug: Bempedoic acid | 1462 | Percent in Lipid, Lipoprotein, and Apolipoprotein |
| 8 | NCT02991118 | Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk |
Drug: Bempedoic acid Drug: placebo |
779 | Percent in Lipid, Lipoprotein, and Apolipoprotein |